Lifelong SIRT-1 overexpression attenuates large artery stiffening with advancing age

Daniel R. Machin¹, Yauling Auduong¹, Venkateswara R. Gogulamudi¹, Yu Liu¹, Md. Torikul Islam², Lisa A. Lesniewski¹,²,⁴, Anthony J. Donato¹,²,³,⁴

¹University of Utah, Department of Internal Medicine, Salt Lake City, UT 84132, USA
²University of Utah, Department of Nutrition and Integrative Physiology, Salt Lake City, UT 84112, USA
³University of Utah, Department of Biochemistry, Salt Lake City, UT 84132, USA
⁴VA Salt Lake City, GRECC, Salt Lake City, UT 84148, USA

Correspondence to: Anthony J. Donato; email: tony.donato@utah.edu

Keywords: arterial stiffness, aging, sirtuins

Copyright: Machin et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Advanced age is accompanied by aortic stiffening that is associated with decreased vascular expression of sirtuin-1 (SIRT-1). Interventions that increase SIRT-1 expression also lower age-related aortic stiffness. Therefore, we sought to determine if lifelong SIRT-1 overexpression would attenuate age-related aortic stiffening. Aortic pulse wave velocity (PWV) was assessed from 3-24 months in SIRT-1 transgenic overexpressing (SIRT¹⁴) and wild-type (WT) mice. To determine the role of aortic structural changes on aortic stiffening, histological assessment of aortic wall characteristics was performed. Across the age range (3-24 mo), PWV was 8-17% lower in SIRT¹⁴ vs. WT (P<0.05). Moreover, the slope of age-related aortic stiffening was lower in SIRT¹⁴ vs. WT (2.1±0.2 vs. 3.8±0.3 cm/sec/mo, respectively). Aortic elastin decreased with advancing age in WT (P<0.05 old vs. young WT), but was maintained in SIRT¹⁴ mice (P>0.05). There was an age-related increase in aortic collagen, advanced glycation end products, and calcification in WT (P<0.05 old vs. young WT). However, this did not occur in SIRT¹⁴ (P>0.05). These findings indicate that lifelong SIRT-1 overexpression attenuates age-related aortic stiffening. These functional data are complemented by histological assessment, demonstrating that the deleterious changes to the aortic wall that normally occur with advancing age are prevented in SIRT¹⁴ mice.

INTRODUCTION

Cardiovascular diseases (CVDs) are the leading cause of death in the United States, and there is a progressive increase in the prevalence of CVD and CVD-related death with advancing age [1]. Among the many deleterious changes to the arterial phenotype that occur with advancing age, the stiffening of the large elastic arteries (i.e., aorta and carotid arteries) is one of the most important, as arterial stiffness is present in several CVD states, such as hypertension, stroke, and left ventricular hypertrophy [2]. Moreover, aortic stiffening is associated with an increased risk of cardiovascular events [3]. Thus, identifying treatments that can prevent or reverse age-related arterial stiffening is of paramount importance.

Sirtuins (SIRTs) are a family of nicotinamide adenine dinucleotide (NAD+)-dependent protein deacetylases [4] and ADP-ribosyltransferases that play a critical role in longevity [5]. Many of the physiological benefits that caloric restriction (CR) has on longevity are attributable to SIRTs, specifically, SIRT-1 [6, 7]. Indeed, genetic SIRT-1 deletion abolishes CR-mediated lifespan extension [8], whereas SIRT-1 overexpression recapitulates the CR phenotype [9]. Our group has demonstrated that declines in vascular SIRT-1 expression in advanced age are associated with age-related large artery stiffening [10]. Moreover, interventions that increase SIRT-1 activity, such as CR [10–12] and dietary supplementation with NAD⁺ intermediates [13, 14] are capable of preventing or lowering age-related aortic stiffness in mice [10–12, 14],
as well as in humans [15]. Although these observations demonstrate the potential cardiovascular benefits of restoring SIRT-1 in the aged vasculature, these studies do not address the protective role that SIRT-1 might play as the vasculature ages.

Recent findings indicate that carotid artery stiffness is lower in old (~20-22 mo) SIRT-1 transgenic overexpressing (SIRT\textsuperscript{TG}) mice, compared to age-matched wild-type (WT) mice [16], but we have observed a similar magnitude of difference in aortic stiffness between young SIRT\textsuperscript{TG} and WT mice (unpublished observations). Thus, it is unclear whether lifelong SIRT-1 overexpression attenuates the rate of arterial stiffening with age or that these animals simply start with lower arterial stiffness in youth. More importantly, no study has comprehensively examined aortic stiffness and structure across the lifespan in SIRT\textsuperscript{TG} mice. Accordingly, the primary aims of the present study were to measure aortic stiffness, as determined by pulse wave velocity (PWV), and structural changes at specific time points across the normal rodent lifespan (~24 months) in SIRT\textsuperscript{TG} and WT mice in an effort to gain a more complete understanding of the role of SIRT-1 in vascular aging. We hypothesized that in youth, aortic stiffness would be lower in SIRT\textsuperscript{TG} mice and that the rate of aortic stiffening would be attenuated in SIRT\textsuperscript{TG} mice. Moreover, we hypothesized that there would be an absence of the deleterious aortic structural changes in SIRT\textsuperscript{TG} mice that occur with advancing age.

**RESULTS**

**Animal characteristics**

Body mass in both young WT and SIRT\textsuperscript{TG} mice were lower than their middle-age counterparts (P<0.05) (Table 1), however, body mass in old SIRT\textsuperscript{TG} mice was similar to young (P>0.05), but lower than age-matched WT mice (P<0.05). In all age groups and in both genotypes, male mice had higher body mass than female mice (data not shown, P<0.05). Heart mass was greater in old WT and SIRT\textsuperscript{TG} mice compared to young mice (P<0.05). Both liver and spleen masses were greater in old WT and SIRT\textsuperscript{TG} mice compared to young mice (P<0.05). Lastly, perigonadal white adipose tissue (WAT) was unchanged across the lifespan and between genotypes (P>0.05).

**Increased aortic SIRT-1 mRNA expression across the lifespan with transgenic SIRT-1 overexpression**

Young and old WT and SIRT\textsuperscript{TG} mice used for gene expression studies were 3.3±0.5, 3.1±0.6, 20.3±1.0, and 20.1±1.2 mo, respectively. Aortic gene expression of SIRT-1 was 3-fold higher in young SIRT\textsuperscript{TG} (3.3±0.5 mo), compared to young WT mice (Figure 1A; P<0.05). Advanced age resulted in a significant decrease in SIRT-1 mRNA expression in both old SIRT\textsuperscript{TG} and WT mice, compared to their young counterparts (P<0.05), still, SIRT-1 expression remained >3-fold higher in old SIRT\textsuperscript{TG} vs. WT mice (P<0.05).

**Age-related aortic stiffening is attenuated with lifelong SIRT-1 overexpression**

A total of 206 aortic PWV measurements (WT: 111 measurements; SIRT\textsuperscript{TG}: 95 measurements) were performed in 93 mice (WT: 24 male and 25 female; SIRT\textsuperscript{TG}: 19 male and 25 female). There were no sex-related differences in PWV, as assessed by 3-factor ANOVA (age X genotype X sex). The slope of increase in aortic PWV with advancing age was greater in WT, compared to SIRT\textsuperscript{TG} mice (Figure 1B; 3.8±0.3 vs. 2.1±0.2 cm/sec, respectively, P<0.05). In each age group, aortic PWV was greater in WT, compared to SIRT\textsuperscript{TG} mice (Figure 1D; P<0.05). In WT mice, aortic PWV increases with age at most 3 mo increments (Figure 1C; P<0.05). Whereas aortic PWV in SIRT\textsuperscript{TG} mice increases from 3 to 9 mo old (Figure 1D; P<0.05), but does not rise significantly until 24 mo old. Anesthetized heart rate was similar between WT and SIRT\textsuperscript{TG} mice in all age groups (Table 2; P>0.05).

**Deleterious age-related structural changes to the aorta are prevented with lifelong SIRT-1 overexpression**

In histological sections of thoracic aortas excised from young, middle-age, and old mice, lumen diameter was greater in both old WT and SIRT\textsuperscript{TG} mice compared with their young and middle-age counterparts (Figure 2A; P<0.05). However, medial cross-sectional area (Figure 2B) was greater in old WT, compared with young and middle-age WT, as well as old SIRT\textsuperscript{TG} mice (P<0.05). After normalizing lumen area (Figure 2C), there was a greater media-to-lumen ratio in old WT, compared with young WT and old SIRT\textsuperscript{TG} mice (P<0.05). Conversely, there were no differences in medial cross-sectional area or media-to-lumen ratio between age groups in SIRT\textsuperscript{TG} mice (Figure 2B, 2C; P>0.05).

Elastin content was lower in old WT, compared with young and middle-age WT, as well as with old SIRT\textsuperscript{TG} mice (Figure 3A; P<0.05). Aortic collagen content was higher in old WT, compared with young WT, as well as old SIRT\textsuperscript{TG} mice (Figure 3B; P<0.05). Although there was no difference in aortic advanced glycation end products (AGEs) intensity in any age group between WT and SIRT\textsuperscript{TG} mice, AGEs intensity was higher in old WT, compared with young WT mice (Figure 3C; P<0.05). Calcified area was higher in middle-age and old WT, compared to young WT, as well as compared...
Table 1. Animal characteristics.

|                  | WT                  | SIRT<sup>TG</sup> |
|------------------|---------------------|-------------------|
|                  | Young | Middle-Age | Old | Young | Middle-Age | Old |
| Male:female N    | 11:12 | 12:10     | 10:4 | 9:10  | 11:6      | 11:10 |
| Age, mo          | 5.9±0.3 | 11.6±0.2<sup>†</sup> | 22.9±0.5<sup>††</sup> | 5.9±0.4 | 11.0±0.3<sup>†</sup> | 23.2±0.2<sup>††</sup> |
| Body mass, g     | 27±1   | 31±1<sup>†</sup> | 32±1<sup>†</sup> | 27±1   | 32±1<sup>†</sup> | 29±1<sup>‡</sup> |
| Heart, mg        | 128±3  | 149±6<sup>†</sup> | 192±8<sup>††</sup> | 132±6  | 146±7      | 181±5<sup>††</sup> |
| Heart:body mass, mg/g | 4.7±0.1 | 4.9±0.1<sup>‡</sup> | 6.0±0.5<sup>††</sup> | 4.8±0.2 | 4.8±0.2<sup>†</sup> | 6.3±0.2<sup>††</sup> |
| Quadriceps, mg   | 194±7  | 200±6     | 171±13<sup>††</sup> | 202±7  | 191±10     | 171±12<sup>†</sup> |
| Quadriceps:body mass, mg/g | 6.9±0.2 | 6.6±0.2<sup>†</sup> | 5.8±0.4<sup>††</sup> | 7.4±0.3 | 6.4±0.3<sup>†</sup> | 5.6±0.3<sup>†</sup> |
| Gastrocnemius, mg| 153±7  | 152±6     | 159±11 | 158±7  | 154±8      | 153±9  |
| Gastrocnemius:body mass, mg/g | 5.5±0.2 | 5.0±0.2<sup>‡</sup> | 5.4±0.3<sup>‡</sup> | 5.7±0.2 | 5.1±0.2<sup>‡</sup> | 5.2±0.3<sup>‡</sup> |
| Soleus, mg       | 12±1   | 11±0      | 12±1  | 11±1   | 11±1       | 11±1   |
| Soleus:body mass, mg/g | 0.42±0.03 | 0.38±0.02 | 0.40±0.03 | 0.40±0.02 | 0.36±0.01 | 0.38±0.02 |
| Liver, g         | 1.4±0.1 | 1.5±0.1<sup>†</sup> | 2.1±0.1<sup>††</sup> | 1.4±0.1 | 1.6±0.1<sup>‡</sup> | 2.0±0.1<sup>††</sup> |
| Spleen, mg       | 84±6   | 88±4      | 179±54<sup>††</sup> | 71±4   | 74±3<sup>‡</sup> | 161±22<sup>††</sup> |
| Perigonadal WAT, mg | 417±69 | 454±53     | 450±105 | 446±68 | 563±63     | 404±110 |

*P<0.05 vs. WT. †P<0.05 vs. Young. ‡P<0.05 vs. Middle-Age. Data are mean±SEM.

White adipose tissue, WAT; Wild-type, WT; SIRT-1 transgenic overexpressing, SIRT<sup>TG</sup>.

**Figure 1.** Aortic SIRT-1 mRNA gene expression (A) in wild-type (WT) and SIRT-1 transgenic overexpressing (SIRT<sup>TG</sup>) mice (N=4-8/group) normalized to Young WT. Scatter plot (B) of aortic pulse wave velocity (PWV) with advancing age in WT and SIRT<sup>TG</sup> mice. Separate regression lines are given for WT and SIRT<sup>TG</sup> mice (dotted lines define 95% confidence intervals). Aortic PWV measured at 3 mo increments in WT (C) and SIRT<sup>TG</sup> (D) mice (N=7-24/group). *P<0.05 vs. WT in same age group. †P<0.05 vs. Young. a, b, c, d, e, f P<0.05 vs. 3, 6, 9, 12, 15, 18, 21 mo, respectively. Data are mean±SEM.
Table 2. Anesthetized heart rate.

| Age, mo | 3  | 6  | 9   | 12  | 15  | 18  | 21  | 24  |
|---------|----|----|-----|-----|-----|-----|-----|-----|
| WT      | 433±9 | 461±13 | 445±16 | 435±14 | 392±10* | 431±17 | 468±11* | 407±11* |
| SIRT<sup>TG</sup> | 439±14 | 437±13 | 460±17 | 463±19 | 414±12 | 430±13 | 448±11 | 416±12 |

*P<0.05 vs. WT, a, b, c, d, e, f, g P<0.05 vs. 3, 6, 9, 12, 15, 18, 21 mo, respectively. Data are mean±SEM.

Wild-type, WT; SIRT-1 transgenic overexpressing, SIRT<sup>TG</sup>.

**Figure 2.** Thoracic aorta lumen diameter (A), medial cross-sectional area (B [CSA]), and media-to-lumen ratio (C) in young, middle-age, and old wild-type (WT) and SIRT-1 transgenic overexpressing (SIRT<sup>TG</sup>) mice. *P<0.05 vs. WT in same age group. †P<0.05 vs. Young. ‡P<0.05 vs. Middle-Age. Data are individual values and means.

Aortic gene expression of superoxide dismutase (SOD) isoforms, SOD1, SOD2, and SOD3, trended toward being lower with advancing age, but were augmented by lifelong SIRT-1 overexpression (Figure 5). Specifically, we observed lower SOD3 gene expression (P<0.05) and a trend toward lower SOD1 and SOD2 gene expression (P=0.07-0.11) in old compared to young WT mice. Whereas, gene expression of all three SOD isoforms was lower in old compared to young SIRT<sup>TG</sup> mice (P<0.05). We also observed higher SOD1 and SOD2 in young and old SIRT<sup>TG</sup> mice compared with age-matched WT mice (P<0.05), while SOD3 was only higher in old SIRT<sup>TG</sup> mice compared with age-matched WT mice (P<0.05).

**DISCUSSION**

In the present study, we comprehensively examined aortic stiffness and structural changes across the normal rodent lifespan in WT and SIRT<sup>TG</sup> mice. In comparison to WT, we observed a lower rate of age-related aortic stiffening in SIRT<sup>TG</sup> mice. Additionally, the deleterious aortic structural changes that occurred in old WT mice, such as medial wall hypertrophy, reduced elastin, accumulation of collagen, AGEs, and aortic calcification were absent in old SIRT<sup>TG</sup> mice. These findings indicate that lifelong SIRT-1 overexpression attenuates aortic stiffening and prevents many of the deleterious structural changes to the aorta that normally occur with advancing age.

**SIRT-1 overexpression and aortic stiffening**

Aortic stiffening with advancing age accompanies decreased vascular SIRT-1 expression and activity [10]. Interestingly, elevations in SIRT-1 activity that are achieved via CR or dietary supplementation with NAD⁺ intermediates are capable of decreasing aortic stiffness in
Figure 3. Total thoracic aortic elastin (A), collagen (B), and advanced glycation end products (C [AGEs]) content in young, middle-age, and old wild-type (WT) and SIRT-1 transgenic overexpressing (SIRT$_{TG}$) mice. Figures are accompanied by representative images of elastin, collagen, and AGEs staining. Black scale bars are equal to 200 µm. *P<0.05 vs. WT. †P<0.05 vs. Young. ‡P<0.05 vs. Middle-Age. Data are individual values and means normalized to Young WT.

Figure 4. Calcified area relative to tunica media area in young, middle-age, and old wild-type (WT) and SIRT-1 transgenic overexpressing (SIRT$_{TG}$) mice. Figure is accompanied by representative images. Black scale bars are equal to 100 µm. *P<0.05 vs. WT. †P<0.05 vs. Young. Data are individual values and means.
old mice [10–12, 14], as well as in older humans [15]. In
the present study, we measured aortic stiffness in WT
and SIRT\textsuperscript{TG} mice at ~3-month intervals from 3-24 mo
old. In addition to having lower aortic stiffness in youth,
the rate of aortic stiffening across the lifespan in SIRT\textsuperscript{TG}
was nearly half that of WT mice. Previously,
whole-body SIRT-1 transgenic overexpression resulted in
lower carotid artery stiffness in old mice, compared to
age-matched WT mice [16]. However, the findings from
that study provide only a snapshot of arterial stiffness at
one time point in advanced age. Whereas in the present
study, through our comprehensive examination aortic
stiffness and structure across the lifespan, provides a
more complete understanding on the role of SIRT-1 in
vascular aging.

Despite the aforementioned benefits of SIRT-1
overexpression, we still observed an increase in aortic
stiffness between some age groups in SIRT\textsuperscript{TG} mice,
although the majority of aortic stiffening in SIRT\textsuperscript{TG} mice
occurred during development. Increases in aortic
stiffness during development are likely due to increases
in body length, as we observed a similar increase in
PWV during youth in WT mice. Thus, increases in aortic
stiffness during development from 3-9 mo are likely
trivial to vascular health. Still, age-related aortic
stiffening in SIRT\textsuperscript{TG} mice did occur at 21-24 mo, which
could be due to declines in aortic SIRT-1 gene
expression in advanced age. However, despite a decrease
in aortic SIRT-1 expression in old SIRT\textsuperscript{TG} mice, SIRT-1
expression remained at least 3-fold higher than that of
age-matched WT mice, but was 50% that of young WT
mice. Increases in SIRT-1 activity via CR or dietary
supplementation with NAD\textsuperscript{+} reverse aortic stiffness in
old mice [10–12, 14]. Considering the age-related
decline in aortic SIRT-1 expression in old SIRT\textsuperscript{TG} mice,
it is possible that either of these interventions could
prevent aortic stiffening that occurred beyond
development in these mice. Although we cannot pinpoint
a direct mechanism in the present study, it is clear that
lifelong SIRT-1 overexpression results in a healthier
vascular phenotype in advanced age. It is important to
note that the benefits of increased SIRT-1 activation do
not need to be lifelong in order to exert vasoprotective
effects, as reductions in aortic stiffness in humans and
mice can occur in the short-term by increasing SIRT-1
activity in advanced age [10–14]. Future studies are
warranted to determine if lifelong maintenance of aortic
SIRT-1 at youthful levels is capable of preventing the
entirety of age-related aortic stiffening that occurs
beyond development.

SIRT-1 overexpression and aortic structure

Unlike aortic stiffness, there was no difference in any
aortic structural variable measured between young WT
and SIRT\textsuperscript{TG} mice. Although with advancing age both
groups demonstrated an increase in aortic lumen
diameter, only WT mice developed deleterious structural
changes to their aortic wall. In WT mice, there was an
increase in aortic medial cross-sectional area with
advancing age, but this did not occur in SIRT\textsuperscript{TG} mice.
Because increased medial cross-sectional area may be a
consequence of the normal age-related widening of the
aortic lumen, we normalized medial cross-sectional area
to lumen area. However, media-to-lumen ratio was also
elevated in old WT compared to both young WT and old
SIRT\textsuperscript{TG} mice. Resistance to medial hypertrophy
/hyperplasia has also been demonstrated in cultured rat
aortic vascular smooth cells that overexpress SIRT-1
[17]. Thus, in the context of aging, it is likely that SIRT-
1 overexpression provides a similar resistance to age-
related medial hypertrophy/hyperplasia. Although lumen
diameter is greater in advancing age in both SIRT\textsuperscript{TG} and

Figure 5. Aortic SOD1, SOD2, and SOD3 mRNA gene expression in young and old wild-type (WT) and SIRT-1 transgenic
overexpressing (SIRT\textsuperscript{TG}) mice (N=5-7/group). *P<0.05 vs. Young WT. †P<0.05 vs. Young SIRT\textsuperscript{TG}. ‡P<0.05 vs. Old WT. Data are mean±SEM
normalized to Young WT.
WT mice, the increased lumen diameter in SIRT$^{\text{TG}}$ mice does not appear to be deleterious because medial hypertrophy does not accompany it.

In addition to aortic wall dimensions, we also examined the structural components of the aorta. In WT mice, there was an age-related reduction in aortic elastin content with a corresponding increase in collagen content. Unlike WT mice, aortic elastin and collagen content were unchanged with advancing age in SIRT$^{\text{TG}}$ mice. Changes in elastin and collagen content are a common alteration in aged arteries [18]. The lack of change in aortic elastin and collagen content with advancing age indicates that SIRT-1 overexpression provides resistance to these deleterious structural changes of aging. It is possible that SIRT-1 exerts these beneficial effects by direct acetylation of collagen and/or elastin, but to the best of our knowledge, this remains unknown. Indeed, SIRT-1 is a positive regulator of tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) and a negative regulator of matrix metalloproteinase-9 (MMP-9) [19, 20], which might provide insight in the ability of SIRT-1 to maintain aortic elastin content in advanced age [21, 22]. Moreover, increased arterial SIRT-1 activity via dietary supplementation with NAD$^+$ intermediates that lowers age-related aortic stiffness also normalizes aortic elastin and collagen content in old mice [14]. The present study is supportive of previous work, indicating that elevated SIRT-1 expression attenuates aortic stiffening and changes in aortic elastin and collagen content in advanced age.

In addition to maintaining a youthful elastin and collagen content, accumulation of AGEs and calcified area in the aorta were also unchanged with advancing age in SIRT$^{\text{TG}}$ mice. Conversely, aortic AGEs and calcium content were both elevated with aging in old WT mice. Direct activation of SIRT-1 via the small molecule, SRT-1720, preserves glucose tolerance in aged rodents, preventing the accumulation of AGEs in SIRT$^{\text{TG}}$ mice via maintenance of normal glucose tolerance in advanced age [23]. In addition to preventing structural changes, maintaining a properly functioning vascular endothelium may also play a pivotal role. SIRT-1 plays a direct role in modulating nitric oxide (NO) and endothelial function via deacetylation and subsequent activation of endothelial NO synthase (eNOS) [24, 25]. Moreover, transgenic whole-body SIRT-1 overexpression prevents the age-related decline in endothelium-dependent vasodilation [16]. Thus, maintaining a properly functioning endothelium in the aged vasculature may also be a benefit of lifelong SIRT-1 overexpression that could impart vasoprotective benefits leading to attenuated aortic stiffness.

Lastly, as mentioned previously, it should be noted that there was a slight, but significant increase in aortic stiffness in old compared to young SIRT$^{\text{TG}}$ mice. Although old SIRT$^{\text{TG}}$ mice had elevated aortic stiffness, their PWV values were similar to that of young WT mice. Thus, these data indicate that the deleterious structural changes to the aorta we observed in older WT mice may have been driven by aortic stiffness after it surpassed a critical threshold in midlife or later. Notably, these structural changes to the aorta were prevented in SIRT$^{\text{TG}}$ mice by maintaining a youthful aortic stiffness across the lifespan. Taken together, these data indicate that lifelong SIRT-1 overexpression prevents deleterious structural changes to the aged aorta, possibly through attenuations in age-related aortic stiffening.

### Experimental considerations

This study is not without limitations. It is well established that SIRT-1 activity increases to elevations in intracellular NAD$^+$ that occur in response to energy/nutrient stresses, such as caloric restriction [26] and exercise [27]. Therefore, higher aortic SIRT-1 gene expression in SIRT$^{\text{TG}}$ permits a greater increase in SIRT-1 activity in response to a given change in NAD$^+$ levels. However, we did not measure NAD$^+$ or make indirect measures of SIRT-1 activation, thus, we are unable to confirm this assumption. Furthermore, we did not measure food consumption or spontaneous cage activity in this study. Therefore, it is possible that the attenuated slope of age-related aortic stiffening may have been due to lower food consumption and/or higher activity levels in SIRT$^{\text{TG}}$ mice. Still, we see no differences in body mass or heart and skeletal muscle masses normalized to body mass between genotypes, suggesting that it is unlikely there were differences in food consumption or activity level that contributed to a lower rate of aortic stiffening in SIRT$^{\text{TG}}$ mice.

### Summary and future directions

These findings indicate that lifelong SIRT-1 overexpression results in lower aortic stiffness at any age across the lifespan, but also slows the rate of aortic stiffening occurring with advancing age. These functional data are complemented by histological assessment of aorta structural characteristics, demonstrating that the deleterious changes to the aorta that normally occur with advancing age, such as medial wall hypertrophy, reduced elastin, accumulation of collagen and AGEs, and aortic calcification are all prevented in mice that are afforded lifelong SIRT-1 overexpression. Although it is unknown if SIRT-1 directly effects any of these processes, we also demonstrated elevated aortic SOD1, SOD2, and SOD3 gene expression in SIRT$^{\text{TG}}$ mice that suggests SIRT-1...
augments antioxidant capacity, which likely attenuates fibrosis, indirectly influencing these processes. Future studies are warranted to determine specific mechanisms by which SIRT-1 exerts its anti-stiffening effects and the use of tissue-specific models of SIRT-1 overexpression or deletion may provide greater mechanistic insight into that area. In summary, these findings indicate that lifelong SIRT-1 overexpression negates many of the deleterious alterations to the aorta that occur with advancing age. Thus, the use of SIRT-1 activators to prevent or reverse the age-related aortic stiffness may be a more viable approach compared to other lifestyle interventions, such as CR.

MATERIALS AND METHODS

Animals

Male and female SIRT\textsuperscript{TG} and WT littermate control mice on a C57BL/6 background were generated from breeding colonies at the Veteran’s Affairs Medical Center-Salt Lake City (VAMC-SLC) [29]. Animals used in this study were housed in the animal care facility at the VAMC-SLC on a 12:12 light:dark cycle and fed standard rodent chow (Envigo, Teklad Diet #8604). Food and water were supplied \textit{ad libitum}.

Quantitative PCR

mRNA expression of SIRT-1 was measured in the aorta of young and old mice by quantitative PCR. Briefly, RNA isolated from aortic tissue was used to synthesize cDNA via QuantiTect Reverse Transcription kit (Qiagen, Inc., Valencia, CA, USA). Quantitative PCR was performed using RT\textsuperscript{2} SYBR\textsuperscript{®} Green quantitative PCR Mastermix (Qiagen, Inc.). Fold change in mRNA expression was calculated as the fold change in expression of target mRNA to 18s rRNA \( \frac{2^{\Delta \Delta C_{\text{t}}}}{\text{Ct}} \) and normalized to young values. 18s primer sequences: forward: TAGAGGGACAAGTGCGTTC; reverse: CGCTGAGCCAGTCAGTGT. SIRT-1 primer sequences: forward: GATTTGCCACAGATCCTGAA; reverse: GTCTACAGCAAGGCGAGCATA. SOD1 primer sequences: forward: AACCAGTTGTGTTGTCAGGAC; reverse: CCAACATGTTTCTTAGATGAG. SOD2 primer sequences: forward: CAGACCTGCCTACGACTATGG; reverse: CTGGTGGCGGTGAGATTGTT. SOD3 primer sequences: forward: CCTCTCTGTCTACGAGCTG; reverse: TCGCCTATCTTCACACCAGG.

Aortic stiffness

Aortic PWV was determined \textit{in vivo} at ~3-month increments over the normal lifespan of C57BL/6 mice (~24 months; 206 measurements in total). Briefly, mice were anesthetized with isoflurane (2-3%) in 100% oxygen at 2 L/min flow rate and placed in the supine position on a heated platform (37°C). Blood velocity waveforms at the transverse aortic arch and at the abdominal aorta were measured simultaneously with two 20-MHz Doppler probes (Indus Instruments, Webster, TX, USA) and recorded using WinDAQ Pro software (DataQ Instruments, Akron, OH, USA). After blood velocities were collected, a precise measurement of the traveled distance between the Doppler probes was recorded using a scientific caliper. The transit time between Doppler sites was determined using the foot-to-foot method with WinDAQ Waveform Browser (DataQ Instruments). Aortic PWV was calculated as the traveled distance divided by the transit time.

Aortic histology

Young (5-7 months), middle-age (12-13 months), and old (23-24 months) SIRT\textsuperscript{TG} and WT mice were sacrificed by exsanguination via cardiac puncture under isoflurane anesthesia. Thoracic aortas were quickly excised and placed in cold (4°C) physiological salt solution. For each mouse, an 2-3 mm aortic ring with perivascular tissue intact was excised from the thoracic aorta and embedded in Optimal Cutting Temperature medium. Aortic rings were sliced into 8-micron sections. Each mouse aorta had 3 to 4 sections per slide, which were averaged. For measures of medial cross-sectional area the lumen border and the outer medial border were traced in ImageJ and internal areas measured. These areas were used to calculate medial cross-sectional area and were calculated as the outer media border area minus the lumen area. Elastin was quantified by Verhoff’s Van Geison stain as percentage of the selected area, as described previously [30]. An 8-bit grayscale was used for densitometric quantification of elastin content with ImageJ. Collagen was quantified by picrosirius red stain as percentage of the selected area, as described previously [10]. Green channel images from an RGB stack were used for densitometric quantification of collagen content with ImageJ (NIH, Bethesda, MA). AGEs were assessed by immunohistochemical visualization, as described previously [31]. Briefly, sections were washed and incubated in primary antibody (1:200, GeneTex 20055) or negative control (2.5% horse serum, Vector Labs) overnight. AGEs were visualized using the appropriate secondary antibody and Vector Labs NovaRed (SK-4800) Peroxidase substrate kit. Three separate, blinded observers (DRM, YA, VRG) scored images on a zero to three scale (0 = absence of appreciable positive stain, 1 = minimal positive stain, 2 = appreciable positive stain, 3 = highly positive stain). Scores for each section were averaged across observers and normalized to negative control sections. Calcium deposition was investigated.
using Von Kossa staining, as previously described [32]. Briefly, sections were fixed with acetone (-20°C) for 10 min, washed 3 times with distilled water, incubated with 1% silver nitrate solution, and exposed to ultraviolet light for 20 min. After a final wash and removal of un-reacted silver with 5% sodium thiosulfate, sections were dehydrated with ethanol and xylene. Calcium particles were observed in visual fields at 10x magnification. The quantification of von Kossa staining was performed as described previously [33]. The surface of the aorta and calcification modules were manually measured with Image J. The calcified area was defined as calcified surface/tunica media (pixels/pixels).

Statistics

Statistics were performed using SPSS (IBM, Chicago, IL). A 2- and 3-factor ANOVA was employed to evaluate differences between age (grouped at 3-month increments) and genotype (age X genotype), as well as between age, genotype, and sex (age X genotype X sex). Although there were differences in body mass and some tissue masses between male and female mice (data not shown), these data are not discussed because we observed no sex-related differences in our primary outcome, PWV. When a significant ANOVA was present, a least significant difference t-test was conducted to determine differences between values. Due to the number of comparisons, a Bonferroni correction was applied to within and between group comparisons for aortic PWV and heart rate data. Multiple linear regression was performed to model the relationships of genotype and/or sex with the age-related aortic stiffening. Statistical significance was set at P<0.05 for all analyses. Data are presented as mean±SEM.

Ethical approval

All animal procedures conformed to the Guide to the Care and Use of Laboratory Animals: Eighth Edition [28] and were approved by the University of Utah and Veteran’s Affairs Medical Center-Salt Lake City Animal Care and Use Committees.

Abbreviations

AGE: advanced glycation end product; CR: caloric restriction; CVD: cardiovascular disease; eNOS: endothelial nitric oxide synthase; MMP: matrix metalloproteinase; NAD: nicotinamide adenine dinucleotide; NO: nitric oxide; PWV: pulse wave velocity; SIRT: sirtuin; SIRT<sup>tg</sup>: sirtuin-1 transgenic overexpressing; SOD: superoxide dismutase; TIMP: tissue inhibitor of matrix metalloproteinase; VAMC-SLC: Veteran’s Affairs Medical Center-Salt Lake City; WAT: white adipose tissue; WT: wild-type.

AUTHOR CONTRIBUTIONS

DR Machin, LA Lesniewski, and AJ Donato contributed to all aspects of the study; including the conception and design, data collection and analysis, and manuscript preparation. Y Auduong, VR Gogulamudi, Y Liu, and MT Islam contributed to the collection and analysis of data and revision of the manuscript.

ACKNOWLEDGMENTS

All experiments were performed in the Translational Vascular Physiology Laboratory at the University of Utah and Veteran’s Affairs Medical Center-Salt Lake City Geriatrics Research Education and Clinical Center.

CONFLICTS OF INTEREST

The authors declare no conflicts of financial and non-financial interest.

FUNDING

This study was funded in part by grants from the National Institute of Health (R01 AG060395, R01 AG050238, R01 AG048366, K02 AG045339, K99 AT010017) and US Department of Veterans Affairs (I01 BX002151).

REFERENCES

1. Benjamin EJ, Muntnner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Das SR, Delling FN, Djousse L, Elkind MS, et al, and American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2019 update: a report from the American heart association. Circulation. 2019; 139:e56–528. https://doi.org/10.1161/CIR.0000000000000659 PMID: 30700139
2. Quinn U, Tomlinson LA, Cockcroft JR. Arterial stiffness. JRSM Cardiovasc Dis. 2012; 1 :cvd.2012.012024. https://doi.org/10.1258/cvd.2012.012024 PMID: 24175072
3. Mitchell GF, Hwang SJ, Vasan RS, Larson MG, Pencina MJ, Hamburg NM, Vita JA, Levy D, Benjamin EJ. Arterial stiffness and cardiovascular events: the framingham heart study. Circulation. 2010; 121:505–11. https://doi.org/10.1161/CIRCULATIONAHA.109.886655 PMID: 20083680
4. Chang HC, Guarente L. SIRT1 and other sirtuins in metabolism. Trends Endocrinol Metab. 2014; 25:138–45.
5. Morselli E, Maiuri MC, Markaki M, Megalou E, Pasparakis A, Palikaras K, Criollo A, Galluzzi L, Malik SA, Vitale I, Michaud M, Madeo F, Tavernarakis N, Kroemer G. Caloric restriction and resveratrol promote longevity through the sirtuin-1-dependent induction of autophagy. Cell Death Dis. 2010; 1:e10. https://doi.org/10.1038/cddis.2009.8 PMID:21364612

6. Cohen HY, Miller C, Bitterman KJ, Wall NR, Hekking B, Kessler B, Howitz KT, Gorospe M, de Cabo R, Sinclair DA. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science. 2004; 305:390–92. https://doi.org/10.1126/science.1099196 PMID:15205477

7. Guarente L. Sirtuins as potential targets for metabolic syndrome. Nature. 2006; 444:868–74. https://doi.org/10.1038/nature05486 PMID:17167475

8. Boily G, Seifert EL, Bevilacqua L, He XH, Sabourin G, Estey C, Moffat C, Crawford S, Saliba S, Jardine K, Xuan J, Evans M, Harper ME, McBurney MW. Sirt1 regulates energy metabolism and response to caloric restriction in mice. PLoS One. 2008; 3:e1759. https://doi.org/10.1371/journal.pone.0001759 PMID:18335035

9. Bordone L, Cohen D, Robinson A, Motta MC, van Veen E, Czopik A, Steele AD, Crowe H, Marmor S, Luo J, Gu W, Guarente L. SIRT1 transgenic mice show phenotypes resembling calorie restriction. Aging Cell. 2007; 6:759–67. https://doi.org/10.1111/j.1474-9726.2007.00335.x PMID:17877786

10. Donato AJ, Walker AE, Magerko KA, Bramwell RC, Black AD, Henson GD, Lawson BR, Lesniewski LA, Seals DR. Life-long caloric restriction reduces oxidative stress and preserves nitric oxide bioavailability and function in arteries of old mice. Aging Cell. 2013; 12:772–83. https://doi.org/10.1111/ace.12103 PMID:23714110

11. Rippe C, Lesniewski L, Connell M, LaRocca T, Donato A, Seals D. Short-term calorie restriction reverses vascular endothelial dysfunction in old mice by increasing nitric oxide and reducing oxidative stress. Aging Cell. 2010; 9:304–12. https://doi.org/10.1111/j.1474-9726.2010.00557.x PMID:20121721

12. Csiszar A, Labinskiy N, Jimenez R, Pinto JT, Ballabh P, Losonczy G, Pearson KJ, de Cabo R, Ungvari Z. Anti-oxidative and anti-inflammatory vasoprotective effects of caloric restriction in aging: role of circulating factors and SIRT1. Mech Ageing Dev. 2009; 130:518–27. https://doi.org/10.1016/j.mad.2009.06.004 PMID:19549533

13. Yoshino J, Mills KF, Yoon MJ, Imai S. Nicotinamide mononucleotide, a key NAD(+)-intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 2011; 14:528–36. https://doi.org/10.1016/j.cmet.2011.08.014 PMID:21982712

14. de Picciotto NE, Gano LB, Johnson LC, Martens CR, Sandler AL, Mills KF, Imai S, Seals DR. Nicotinamide mononucleotide supplementation reverses vascular dysfunction and oxidative stress with aging in mice. Aging Cell. 2016; 15:522–30. https://doi.org/10.1111/acel.12461 PMID:26970090

15. Martens CR, Denman BA, Mazzo MR, Armstrong ML, Reisdorph N, McQueen MB, Chonchol M, Seals DR. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD⁺ in healthy middle-aged and older adults. Nat Commun. 2018; 9:1286. https://doi.org/10.1038/s41467-018-03421-7 PMID:29599478

16. Wan YZ, Gao P, Zhou S, Zhang ZQ, Hao DL, Lian LS, Li YJ, Chen HZ, Liu DP. SIRT1-mediated epigenetic downregulation of plasminogen activator inhibitor-1 prevents vascular endothelial replicative senescence. Aging Cell. 2014; 13:890–99. https://doi.org/10.1111/ace.12247 PMID:25040736

17. Li L, Gao P, Zhang H, Chen H, Zheng W, Lv X, Xu T, Wei Y, Liu D, Liang C. SIRT1 inhibits angiotensin II-induced vascular smooth muscle cell hypertrophy. Acta Biochim Biophys Sin (Shanghai). 2011; 43:103–09. https://doi.org/10.1093/abbs/gmq104 PMID:21118843

18. Donato AJ, Machin DR, Lesniewski LA. Mechanisms of dysfunction in the aging vasculature and role in age-related disease. Circ Res. 2018; 123:825–48. https://doi.org/10.1161/CIRCRESAHA.118.312563 PMID:30355078

19. Nakamaru Y, Vuppusetty C, Wada H, Milne JC, Ito M, Rossios C, Elliot M, Hogg J, Kharitonov S, Goto H, Bemis JE, Elliott P, Barnes PJ, Ito K. A protein deacetylase SIRT1 is a negative regulator of metalloproteinase-9. FASEB J. 2009; 23:2810–19. https://doi.org/10.1096/fj.08-125468 PMID:19376817

20. Yao H, Hwang JW, Sundar IK, Friedman AE, McBurney MW, Guarente L, Gu W, Kinnula VL, Rahman I. SIRT1 redresses the imbalance of tissue inhibitor of matrix
metalloproteinase-1 and matrix metalloproteinase-9 in the development of mouse emphysema and human COPD. Am J Physiol Lung Cell Mol Physiol. 2013; 305:L615–24. https://doi.org/10.1152/ajplung.00249.2012 PMID:24039251

21. Yasmin, McEniery CM, Wallace S, Dakham Z, Pulsalkar P, Maki-Petaja K, Ashby MJ, Cockcroft JR, Wilkinson IB. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol. 2005; 25:372. https://doi.org/10.1161/01.ATV.0000151373.33830.41 PMID:15556929

22. Allaire E, Forough R, Clowes M, Starcher B, Clowes AW. Local overexpression of TIMP-1 prevents aortic aneurysm degeneration and rupture in a rat model. J Clin Invest. 1998; 102:1413–20. https://doi.org/10.1172/JCI2909 PMID:9769334

23. Mitchell SJ, Martin-Montalvo A, Mercken EM, Palacios HH, Ward TM, Abulwerdi G, Minor RK, Vlasuk GP, Ellis JL, Sinclair DA, Dawson J, Allison DB, Zhang Y, et al. The SIRT1 activator SRT1720 extends lifespan and improves health of mice fed a standard diet. Cell Rep. 2014; 6:836–43. https://doi.org/10.1016/j.celrep.2014.01.031 PMID:24582957

24. Donato AJ, Magerko KA, Lawson BR, Durrant JR, Lesniewski LA, Seals DR. SIRT-1 and vascular endothelial dysfunction with ageing in mice and humans. J Physiol. 2011; 589:4545–54. https://doi.org/10.1113/jphysiol.2011.211219 PMID:21746786

25. Mattagajasingh I, Kim CS, Naqvi A, Yamamori T, Hoffman TA, Jung SB, DeRicco J, Kasuno K, Irani K. SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase. Proc Natl Acad Sci USA. 2007; 104:14855–60. https://doi.org/10.1073/pnas.0704329104 PMID:17785417

26. Chen D, Bruno J, Easlon E, Lin SJ, Cheng HL, Alt FW, Guarente L. Tissue-specific regulation of SIRT1 by calorie restriction. Genes Dev. 2008; 22:1753–57. https://doi.org/10.1101/gad.1650608 PMID:18550784

27. Egan B, Zierath JR. Exercise metabolism and the molecular regulation of skeletal muscle adaptation. Cell Metab. 2013; 17:162–84. https://doi.org/10.1016/j.cmet.2012.12.012 PMID:23395166

28. Council NR. (2010). Guide for the care and use of laboratory animals: National Academies Press.

29. Banks AS, Kon N, Knight C, Matsumoto M, Gutiérrez-Juárez R, Rossetti L, Gu W, Accili D. SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab. 2008; 8:333–41. https://doi.org/10.1016/j.cmet.2008.08.014 PMID:18840364

30. Raub CB, Mahon S, Narula N, Tromberg BJ, Brenner M, George SC. Linking optics and mechanics in an in vivo model of airway fibrosis and epithelial injury. J Biomed Opt. 2010; 15:015004. https://doi.org/10.1117/1.3322296 PMID:20210444

31. Henson GD, Walker AE, Reihl KD, Donato AJ, Lesniewski LA. Dichotomous mechanisms of aortic stiffening in high-fat diet fed young and old B6D2F1 mice. Physiol Rep. 2014; 2:e00268. https://doi.org/10.1002/phy2.268 PMID:24760522

32. Bennett BJ, Scatena M, Kirk EA, Rattazzi M, Varon RM, Averill M, Schwartz SM, Giachelli CM, Rosenfeld ME. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/ mice. Arterioscler Thromb Vasc Biol. 2006; 26:2117–24. https://doi.org/10.1161/01.ATV.0000236428.91125.e6 PMID:16840715

33. Voelkl J, Alesutan I, Leibrock CB, Quintana-Martinez L, Kuhn V, Feger M, Mia S, Ahmed MS, Rosenblatt KP, Kuro-O M, Lang F. Spironolactone ameliorates PIT1-dependent vascular osteoinduction in klotho-hypomorphic mice. J Clin Invest. 2013; 123:812–22. https://doi.org/10.1172/JCI64093 PMID:23298834